Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.alxoncology.com
ALX Oncology News Releases
Get the latest updates from ALX Oncology News Releases directly as they happen.
Follow now 48 followers
Latest posts
Last updated 1 day ago
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
1 day ago
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer...
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025
8 days ago
SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- ALX Oncology...
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma
14 days ago
- Data to be presented at AACR 2025 Annual Meeting suggest the...
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints
15 days ago
In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept...
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
about 1 month ago
ALX2004 is a potential best- and first-in-class antibody-drug conjugate (ADC) for the...
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
2 months ago
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept...
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
2 months ago
Event to include updates on ongoing evorpacept clinical development program and introduction...
ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event
2 months ago
Event to include updates on ongoing evorpacept clinical development program and introduction...
ALX Oncology to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
2 months ago
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ALX Oncology...
ALX Oncology to Host Virtual R&D Day on March 5, 2025
3 months ago
Company leadership and external key opinion leaders to highlight clinical program progress...
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
4 months ago
Oral presentation at 2025 ASCO Gastrointestinal Cancers Symposium today highlights e vorpacept...
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
4 months ago
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- ALX Oncology...